Morning Briefing
Summaries of health policy coverage from major news organizations
Antibiotic Resistance In Humans And Animals Closely Linked
In a study billed as the first of its kind, an international team of researchers report that the association between antibiotic consumption and antimicrobial resistance (AMR) in humans and animals is a "two-way street." The modeling study, published yesterday in the Lancet Planetary Health, used global data on drug-resistant pathogens and human and animal antibiotic consumption to show that in both humans and food-producing animals, unsurprisingly, increased antibiotic use is associated with increased AMR. But the model also estimated that increased antibiotic use by food-producing animals is associated with increased resistance in the bacterial pathogens that infect humans, while increased antibiotic use in humans is linked to increased animal AMR rates. (Dall, 4/4)
Scientists have demonstrated that, globally, the association between antibiotic consumption and antimicrobial resistance (AMR) between human and animals goes both ways. (London School of Hygience and Tropical Medicine, 4/4)
Monoclonal antibodies (mAbs) given within 2 days of a COVID-19 diagnosis lowered the risk of hospitalization or death by 39%, estimates a hypothetical randomized study using observational data published today in the Annals of Internal Medicine. (Van Buesekom, 4/4)
Pardes Biosciences Inc said on Monday it will suspend further clinical development of its experimental antiviral treatment pomotrelvir, after the drug failed a mid-stage trial for treating COVID-19, and will explore strategic alternatives which may include a sale of the company. (4/3)
A statistical shortfall didn’t dissuade the FDA from authorizing an anti-inflammatory therapy for treating COVID-19. The FDA has granted an emergency use authorization for InflaRx’s vilobelimab to treat critically ill COVID patients, the German company said in a press release Monday. (Liu, 4/4)
Sanofi and the Biomedical Advanced Research and Development Authority (BARDA) are expanding their capacity to manufacture flu shots. They are breaking ground on a two-story formulation and filling facility at the company’s sprawling campus in Swiftwater, Pennsylvania. (Dunleavy, 4/4)
Camber Pharmaceuticals issued a voluntary recall of one lot of atovaquone oral suspension used to treat a form of pneumonia. The recall is due to the potential of microbial contamination of Bacillus cereus. (Keenan, 4/4)
Fresh insights into how our bodies interact with the microbes living in our guts suggest that a two-drug combination may offer a new way to treat inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. (Cincinnati Children's Hospital Medical Center, 4/4)
